SAN DIEGO, June 30, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
What if I purchased Regeneron common stock? If you purchased Regeneron common stock and suffered significant losses on your investment, join our investigation now:
https://www.johnsonfistel.com/investigations/regeneron-pharmaceuticals
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471
There is no cost or obligation to you.
What is Johnson Fistel investigating? On June 27, 2023, the company received a response letter from the FDA which declined the approval of its application for an 8mg dose of aflibercept, marketed in the U.S. as Eylea. The company stated that the denial was due to an ongoing review of third-party filer findings.
Following this news, Regeneron’s stock dropped 8.7% on June 27, 2023.
What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or jimb@johnsonfistel.com.
Contact:
Johnson Fistel, LLP
Jim Baker, Lead Securities Analyst
Telephone: (619) 814-4471
Email: jimb@johnsonfistel.com
